Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
naveglitazar · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| naveglitazar | DRUG | - |
Inclusion Criteria: * Diagnosis of Type 2 Diabetes for at least 3 months. * Diabetes managed with diet and exercise alone or with either metformin or sulfonylurea alone as an adjunct to diet and exercise. * Diabetes therapy must be unchanged for at least 3 months prior to screening. * Females must ...
Naveglitazar is an investigational oral small molecule developed by Eli Lilly and Company for the treatment of non-insulin-dependent diabetes mellitus, also known as type 2 diabetes. It was studied as an oral antidiabetic agent and reached Phase 2 clinical development.
Naveglitazar was being evaluated for the treatment of Diabetes Mellitus, Non-Insulin-Dependent, or type 2 diabetes, in adults. It is an oral antidiabetic agent, meaning it was designed to be taken by mouth to help manage blood glucose in people with type 2 diabetes.
Naveglitazar targets PPARG and PPARA, two nuclear receptors, as an agonist. By activating both PPAR gamma and PPAR alpha, the small molecule acts on pathways involved in glucose and lipid regulation. Dual PPAR alpha and gamma agonism is the mechanism studied for oral antidiabetic activity.
Naveglitazar was developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the clinical evaluation of the compound as an oral antidiabetic agent for type 2 diabetes.
Naveglitazar reached Phase 2 clinical development. It is investigational and is not an approved medicine. The Phase 2 study of naveglitazar has been completed, and no trials of the drug are currently listed as active.
Naveglitazar was studied in one Phase 2 trial, NCT00065312, titled An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes. That trial enrolled adults aged 18 years and older in the United States, was uncontrolled, and has been completed.